Trial of Intravenous Immune Globulin in Dermatomyositis I | UPDATES IN MEDICINE
Trial of Intravenous Immune Globulin in Dermatomyositis
In this 16-week trial involving adults with dermatomyositis, the percentage of patients with a response of at least minimal improvement based on a composite score of disease activity was significantly greater among those who received IVIG than among those who received placebo. IVIG was associated with adverse events, including thromboembolism.
